NOV 2 0 2007 W Express Mail Labe No. EM015925413US 11-23-07

6

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/570,117

TRANSMITTAL FORM Filing Date First Named Inventor Art Unit

(to be used for all correspondence after initial filing)

Total Number	οf	Pages	in	This	Submission
i otal i tallioci	٠,	, ages		11110	Cubilliagion

Application	Number	10/570,117			
Filing Date		February 28, 2006			
First Named	Inventor	Joerg Heyer			
Art Unit		Not Yet Assigned	•		
Examiner N	ame	Not Yet Assigned			
Attorney Do	cket Number	GEN/022			

		ENCLOSURES (Check all that a	apply)		
Fee Transmittal	Form	Drawing(s)	After Allowance Communication to TC		
Fee Attacl	ned	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences		
Amendment/Re	oly	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final		Petition to Convert to a Provisional Application	Proprietary Information		
Affidavits/	declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter		
Extension of Tin	ne Request	Terminal Disclaimer	Other Enclosure(s) (please Identify below):		
Express Abando	onment Request	Request for Refund	Postcard		
Information Disc	losure Statement	CD, Number of CD(s) Landscape Table on CD			
PTO/SB/08a (in With 21 cited reference		Remarks			
	sponse to Missing Parts/ complete Application The Director is hereby authorized to charge payment of any additional fees				
required in connection with this Information Disclosure Statement to De Account No. 06-1075, Order No. 001581-0211. A duplicate copy of this is transmitted herewith.					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name Ropes & Gray LLP (Customer No. 1473)					
Signature Connie Word					
Printed name Connie Wong					
Date No	vember 20, 2007		Reg. No. L0104		
EXPRESS MAIL CERTIFICATION (EM015925413US)					
I hereby certify that this paper/fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Mail Stop Amendment, Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.					
Signature Sual Schlie					
Typed or printed name		h Schlie	Date November 20, 2007		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

E /4 Express Mai	il Label No. EM015925413	IIS			•	
2 0 2007 When	the Paperwork Reduction Act of 1995	, no persons	U.S. Patent	A at and Tra	PTO/SB/21 (09-04) pproved for use through 07/31/2006. OMB 0651-0031 demark Office; U.S. DEPARTMENT OF COMMERCE mation unless it displays a valid OMB control number.	
<i>(</i> §/			Application Number		0/570,117	
TRANSMITTAL			Filing Date		ebruary 28, 2006	
TRANSMITTAL FORM		First Named Inventor		loerg Heyer		
		Art Unit		Not Yet Assigned		
(to be used for all correspondence after initial filing)		Examiner Name		Not Yet Assigned		
Total Number of Pages in This Submission		Attorney Docket Number		GEN/022		
		ENCL	2011050			
		ENCLU	OSURES (Check all that ap	ply)		
Fee Trans	smittal Form	□□□□	rawing(s)	ł	After Allowance Communication to TC	
Fee	e Attached	Li	censing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendme	ent/Reply	P	etition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
Afte	er Final	☐ P	etition to Convert to a rovisional Application		Proprietary Information	
Affic	davits/declaration(s)		ower of Attorney, Revocation nange of Correspondence Addres	.	Status Letter	
Extension	of Time Request	l —	erminal Disclaimer		Other Enclosure(s) (please Identify below):	
Express A	Abandonment Request	R	equest for Refund		Postcard	
Informatio	on Disclosure Statement		D. Number of CD(s)			
PTO/SB/08 With 21 cit	8a (in duplicate) ed references	Remar	Landscape Table on CD			
Response	Response to Missing Parts/ Incomplete Application The Director is hereby authorized to charge payment of any additional			rge payment of any additional fees		
		required	i in connection with this Info	ormati	on Disclosure Statement to Deposit	
Response to Missing Parts Account			t No. 06-1075, Order No. <u>001581-0211</u> . A duplicate copy of this letter mitted herewith.			
	0. 0. 1. 1.02 01 1.33	is liaiisi	mited Herewith.			
	SIGNATU	RE OF	APPLICANT, ATTORNEY	OR A	GENT	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Ropes & Gray LLP (Customer No. 1473)						
Signature	Connie Word					
Printed name	Connie Wong	·				
Date	November 20, 2007			Reg. No	110104	
20, 2007				cg. 140	D. L0104	
	EXPRES	S MAIL	CERTIFICATION (EM015	92541	3US)	
I hereby certify that this paper/fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Mail Stop Amendment, Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.						
Signature Sual Sable						
Typed or printed name Sarah Schlie Date November 20, 2007					Date November 20, 2007	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including attening, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date November 20, 2007

Attorney Docket No.: GEN/022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Joerg Heyer et al.

Application No.

10/570,117

Confirmation No.:

8044

Filed

February 28, 2006

For

TUMOR-SPECIFIC EXPRESSION OF REPORTER GENES

Group Art Unit

Not Yet Assigned

Examiner

Not Yet Assigned

New York, New York November 20, 2007

Mail Stop: Amendment Hon. Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorneys, make of record the documents listed below. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), applicants have not provided paper copies of the U.S. Patent Documents, which are listed on the accompanying Form PTO/SB/08A (submitted in duplicate).

Applicants respectfully request that the documents listed below and on Form PTO/SB/08A be (1) fully considered by the Examiner prior to issuance of any patent from this application and (2) printed on any patent issuing from this application.

Applicants also request that a copy of the enclosed Form PTO/SB/08A duly initialed by the Examiner be forwarded to the undersigned with the next communication.

Other Documents

Bao, R., et al., "Activation of cancer-specific gene expression by the survivin promoter," J. of the National Cancer Inst. 94:522-528 (2002).

Chatterjee, B., et al., "BMP regulation of the mouse connexin43 promoter in osteoblastic cells and embryos," Cell Communication and Adhesion 10:37-50 (2003).

Contag, et al., "Advances in in vivo bioluminescence imaging of gene expression," Annual Review of Biomed. Eng. 4:235-260 (2002).

Coralli, C., et al., "Limitations of the reporter green fluorescent protein under simulated tumor conditions," Cancer Research 61:4784-4790 (2001).

Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," Methods 26:199-213 (2002).

Giles et al., "Caught up in a Wnt storm: Wnt signaling in cancer," Biochimica et Biophysica Acta 1653:1-24 (2003).

Hannon, "RNA interference," Nature 418:244-251 (2002).

Jacks et al., "Effects of an Rb mutation in the mouse," Nature 359:295-300 (1992).

Kim et al., "Survivin and molecular pathogenesis of colorectal cancer," Lancet 362:205-209 (2003).

Massuda, E.S., et al., "Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells," *Proc. Nat'l. Acad. Sci.* 94:14701-14706 (1997).

McManus, M.T., et al., "Gene silencing in mammals by small interfering RNAs," *Nature Reviews* 3:737-747 (2002).

Staal, F.J.T., et al., "Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells," *Int'l Immunology* 11:317-323 (1999).

Vooijs et al., "Noninbasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice," Cancer Res. 62(6):1862-1867 (2002).

Young, M.R. et al., "Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion," *Proc. Natl. Acad. Sci.* 96:9827-9832 (1999).

Zhong, S., et al., "Organ-specific activation of acitvator protein-1 in transgenic mice by 12-O-tetradecanoylphorbol-13-acetate with different administration methods," Cancer Research 61:4084-4091 (2001).

Zhong, S.P., et al., "Organ-specific distribution of AP-1 in AP-1 luciferase transgenic mice during the maturation process," Am. J. Physiol Regul Integr Comp Physiol 280:R376-R381 (2001).

This Statement is being submitted more than three months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Director, however, is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075, Order No. 001581-0211.

Respectfully submitted,

Jane T. Gunnison (Reg. No. 38,479)

Connie Wong (Reg. No. L0104)

Connewons

Attorneys for Applicants

ROPES & GRAY LLP

Customer No. 1473

1211Avenue of the Americas

New York, New York 10036

Tel.: (212) 596-9000 Fax.: (212) 596-9090



Attorney Docket No.: GEN/022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Joerg Heyer et al.

Application No.

10/570,117

Confirmation No.:

8044

Filed

February 28, 2006

For

TUMOR-SPECIFIC EXPRESSION OF REPORTER GENES

Group Art Unit

Not Yet Assigned

Examiner

Not Yet Assigned

New York, New York November 20, 2007

Mail Stop: Amendment

Hon. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorneys, make of record the documents listed below. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), applicants have not provided paper copies of the U.S. Patent Documents, which are listed on the accompanying Form PTO/SB/08A (submitted in duplicate).

Applicants respectfully request that the documents listed below and on Form PTO/SB/08A be (1) fully considered by the Examiner prior to issuance of any patent from this application and (2) printed on any patent issuing from this application.

Applicants also request that a copy of the enclosed Form PTO/SB/08A duly initialed by the Examiner be forwarded to the undersigned with the next communication.

Other Documents

Bao, R., et al., "Activation of cancer-specific gene expression by the survivin promoter," J. of the National Cancer Inst. 94:522-528 (2002).

Chatterjee, B., et al., "BMP regulation of the mouse connexin43 promoter in osteoblastic cells and embryos," Cell Communication and Adhesion 10:37-50 (2003).

Contag, et al., "Advances in in vivo bioluminescence imaging of gene expression," Annual Review of Biomed. Eng. 4:235-260 (2002).

Coralli, C., et al., "Limitations of the reporter green fluorescent protein under simulated tumor conditions," Cancer Research 61:4784-4790 (2001).

Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," Methods 26:199-213 (2002).

Giles et al., "Caught up in a Wnt storm: Wnt signaling in cancer," Biochimica et Biophysica Acta 1653:1-24 (2003).

Hannon, "RNA interference," Nature 418:244-251 (2002).

Jacks et al., "Effects of an Rb mutation in the mouse," Nature 359:295-300 (1992).

Kim et al., "Survivin and molecular pathogenesis of colorectal cancer," Lancet 362:205-209 (2003).

Massuda, E.S., et al., "Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells," *Proc. Nat'l. Acad. Sci.* 94:14701-14706 (1997).

McManus, M.T., et al., "Gene silencing in mammals by small interfering RNAs," *Nature Reviews* 3:737-747 (2002).

Staal, F.J.T., et al., "Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells," *Int'l Immunology* 11:317-323 (1999).

Vooijs et al., "Noninbasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice," Cancer Res. 62(6):1862-1867 (2002).

Young, M.R. et al., "Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion," *Proc. Natl. Acad. Sci.* 96:9827-9832 (1999).

Zhong, S., et al., "Organ-specific activation of acitvator protein-1 in transgenic mice by 12-O-tetradecanoylphorbol-13-acetate with different administration methods," *Cancer Research* 61:4084-4091 (2001).

Zhong, S.P., et al., "Organ-specific distribution of AP-1 in AP-1 luciferase transgenic mice during the maturation process," Am. J. Physiol Regul Integr Comp Physiol 280:R376-R381 (2001).

This Statement is being submitted more than three months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Director, however, is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075, Order No. 001581-0211.

Respectfully submitted,

Jane T. Gunnison (Reg. No. 38,479)

Connie Wong (Reg. No. L0104)

Conniewons

Attorneys for Applicants ROPES & GRAY LLP

Customer No. 1473

1211Avenue of the Americas

New York, New York 10036

Tel.: (212) 596-9000 Fax.: (212) 596-9090